Radiotherapy & Oncology
Volume 92, Issue 3 , Pages 293-298 , September 2009

Molecular radiation biology: Perspectives for radiation oncology

Received 14 August 2009 ,Accepted 15 August 2009.

References 

  1. Iliakis G, Wu W, Wang M, Terzoudi GI, Pantelias GE. In: Chromosome alterations. Berlin Heidelberg: Springer Verlag; 2007. p. 67–85.
  2. Nussenzweig A, Nussenzweig MC. A backup DNA repair pathway moves to the forefront. Cell. 2007;131:223–225
  3. McVey M, Lee SE. MMEJ repair of double-strand breaks (director’s cut): deleted sequences and alternative endings. Trends Genet. 2008;24:529–538
  4. Bennardo N, Cheng A, Huang N, Stark JM. Alternative-NHEJ is a mechanistically distinct pathway of mammalian chromosome break repair. PLoS Genet. 2008;4:e1000110
  5. Ahmad A, Robinson AR, Duensing A, et al. ERCC1-XPF endonuclease facilitates DNA double-strand break repair. Mol Cell Biol. 2008;28:5082–5092
  6. Audebert M, Salles B, Calsou P. Involvement of poly(ADP-ribose) polymerase-1 and XRCC1/DNA ligase III in an alternative route for DNA double-strand breaks rejoining. J Biol Chem. 2004;279:55117–55126
  7. Wang H, Rosidi B, Perrault R, et al. DNA ligase III as a candidate component of backup pathways of nonhomologous end joining. Cancer Res. 2005;65:4020–4030
  8. Audebert M, Salles B, Calsou P. Effect of double-strand break DNA sequence on the PARP-1 NHEJ pathway. Biochem Biophys Res Commun. 2008;369:982–988
  9. Audebert M, Salles B, Weinfeld M, Calsou P. Involvement of polynucleotide kinase in a poly(ADP-ribose) polymerase-1-dependent DNA double-strand breaks rejoining pathway. J Mol Biol. 2006;356:257–265
  10. Wang M, Wu W, Wu W, et al. PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways. Nucleic Acids Res. 2006;34:6170–6178
  11. Singh SK, Wu W, Wu W, Wang M, Iliakis G. Extensive repair of DNA double-strand breaks in cells deficient in the DNA-PK-dependent pathway of NHEJ after exclusion of heat-labile sites. Radiat Res. 2009;172:152–164
  12. Iliakis G. Backup pathways of NHEJ in cells of higher eukaryotes: Cell cycle dependence. Radiother Oncol. 2009;92:310–315
  13. Wu W, Wang M, Mussfeldt T, Iliakis G. Enhanced use of backup pathways of NHEJ in G2 in Chinese hamster mutant cells with defects in the classical pathway of NHEJ. Radiat Res. 2008;170:512–520
  14. Wu W, Wang M, Wu W, Singh SK, Mussfeldt T, Iliakis G. Repair of radiation induced DNA double strand breaks by backup NHEJ is enhanced in G2. DNA Repair (Amst). 2008;7:329–338
  15. Kasten-Pisula U, Menegakis A, Brammer I, Borgmann K, Mansour WY, Degenhardt S, et al. The extreme radiosensitivity of the squamous cell carcinoma SKX is due to a defect in double-strand break repair. Radiother Oncol. 2009;90:257–264
  16. Koch K, Wrona A, Dikomey E, Borgmann K. Impact of homologous recombination on individual cellular radiosensitivity. Radiother Oncol. 2009;90:265–272
  17. Simonsson M, Qvarnström F, Nyman J, Johansson KA, Garmo H, Turesson I. Low-dose hypersensitive gammaH2AX response and infrequent apoptosis in epidermis from radiotherapy patients. Radiother Oncol. 2008;88:388–397
  18. Vermeulen C, Verwijs-Janssen M, Begg AC, Vens C. Cell cycle phase dependent role of DNA polymerase beta in DNA repair and survival after ionizing radiation. Radiother Oncol. 2008;86:391–398
  19. Kasten-Pisula U, Vronskaja S, Overgaard J, Dikomey E. In normal human fibroblasts variation in DSB repair capacity cannot be ascribed to radiation-induced changes in the localisation, expression or activity of major NHEJ proteins. Radiother Oncol. 2008;86:321–328
  20. Olive PL, Banáth JP, Keyes M. Residual gammaH2AX after irradiation of human lymphocytes and monocytes in vitro and its relation to late effects after prostate brachytherapy. Radiother Oncol. 2008;86:336–346
  21. Bristow RG, Ozcelik H, Jalali F, Chan N, Vesprini D. Homologous recombination and prostate cancer: a model for novel DNA repair targets and therapies. Radiother Oncol. 2007;83:220–230
  22. Lavin MF, Kozlov S. DNA damage-induced signalling in ataxia-telangiectasia and related syndromes. Radiother Oncol. 2007;83:231–237
  23. Welsh JW, Ellsworth RK, Kumar R, Fjerstad K, Martinez J, Nagel RB, et al. Rad51 protein expression and survival in patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2009;74:1251–1255
  24. Powell SN, Bindra RS. Targeting the DNA damage response for cancer therapy. DNA Repair (Amst). 2009;[Epub ahead of print]
  25. Mukherjee B, McEllin B, Camacho CV, Tomimatsu N, Sirasanagandala S, Nannepaga S, et al. EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma. Cancer Res. 2009;69:4252–4259
  26. Chan N, Koch CJ, Bristow RG. Tumour hypoxia as a modifier of DNA strand break and cross-link repair. Curr Mol Med. 2009;9:401–410
  27. Lara PC, Lloret M, Clavo B, Apolinario RM, Bordón E, Rey A, et al. Hypoxia downregulates Ku70/80 expression in cervical carcinoma tumours. Radiother Oncol. 2008;89:222–226
  28. Bristow RG, Ozcelik H, Jalali F, Chan N, Vesprini D. Homologous recombination and prostate cancer: a model for novel DNA repair targets and therapies. Radiother Oncol. 2007;83:220–230
  29. Chan N, Koritzinsky M, Zhao H, Bindra R, Glazer PM, Powell S, et al. Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance. Cancer Res. 2008;68:605–614
  30. Bristow RG, Hill RP. Hypoxia and metabolism, hypoxia, DNA repair and genetic instability. Nat Rev Cancer. 2008;8:180–192
  31. Liu SK, Coackley C, Krause M, Jalali F, Chan N, Bristow RG. A novel poly(ADP-ribose) polymerase inhibitor, ABT-888, radiosensitizes malignant human cell lines under hypoxia. Radiother Oncol. 2008;88:258–268
  32. Borkamo ED, Fluge O, Mella O, Akslen LA, Bruland O, Dahl O. Hyperthermia improves the antitumour effect of metronomic cyclophosphamide in a rat transplantable brain tumour. Radiother Oncol. 2008;86:435–442
  33. Folkvord S, Flatmark K, Seierstad T, Røe K, Rasmussen H, Ree AH. Inhibitory effects of oxaliplatin in experimental radiation treatment of colorectal carcinoma: does oxaliplatin improve 5-fluorouracil-dependent radiosensitivity?. Radiother Oncol. 2008;86:428–434
  34. Haykal J, Fernainy P, Itani W, Haddadin M, Geara F, Smith C, et al. Radiosensitization of EMT 6 mammary carcinoma cells by 2-benzoyl-3-phenyl-6,7-dichloroquinoxaline 1,4-dioxide. Radiother Oncol. 2008;86:412–418
  35. Kasten-Pisula U, Windhorst S, Dahm-Daphi J, Mayr G, Dikomey E. Radiosensitization of tumour cell lines by the polyphenol Gossypol results from depressed double-strand break repair and not from enhanced apoptosis. Radiother Oncol. 2007;83:296–303
  36. Carlson JJ, Garrison LP, Ramsey SD, Veenstra DL. Epidermal growth factor receptor genomic variation in NSCLC patients receiving tyrosine kinase inhibitor therapy: a systematic review and meta-analysis. J Cancer Res Clin Oncol. 2009;[Epub ahead of print]
  37. Bernier J, Bentzen SM, Vermorken JB. Molecular therapy in head and neck oncology. Nat Rev Clin Oncol. 2009;6:266–277
  38. Palayekar MJ, Herzog TJ. The emerging role of epidermal growth factor receptor inhibitors in ovarian cancer. Int J Gynecol Cancer. 2008;18:879–890
  39. Karpel-Massler G, Schmidt U, Unterberg A, Halatsch ME. Therapeutic inhibition of the epidermal growth factor receptor in high-grade gliomas: where do we stand?. Mol Cancer Res. 2009;7:1000–1012
  40. Bedard PL, de Azambuja E, Cardoso F. Beyond trastuzumab: overcoming resistance to targeted HER-2 therapy in breast cancer. Curr Cancer Drug Targets. 2009;9:148–162
  41. Chau I, Cunningham D. Treatment in advanced colorectal cancer: what; when and how?. Br J Cancer. 2009;100:1704–1719
  42. Kopper L, Tímár J. Genomics of renal cell cancer – does it provide breakthrough?. Pathol Oncol Res. 2006;12:5–11
  43. Pancreatic Longo R, Cacciamani F, Naso G, Gasparini G. Cancer: from molecular signature to target therapy. Crit Rev Oncol Hematol. 2008;68:197–211
  44. Nyati MK, Morgan MA, Feng FY, Lawrence TS. Integration of EGFR inhibitors with radiochemotherapy. Nat Rev Cancer. 2006;6:876–885
  45. Dittmann K, Mayer C, Kehlbach R, Rodemann HP. The radioprotector Bowman–Birk proteinase inhibitor stimulates DNA repair via epidermal growth factor receptor phosphorylation and nuclear transport. Radiother Oncol. 2008;86:375–382
  46. Casa AJ, Dearth RK, Litzenburger BC, Lee AV, Cui X. The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance. Front Biosci. 2008;13:3273–3287
  47. Lal B, Xia S, Abounader R, Laterra J. Targeting the c-Met pathway potentiates glioblastoma responses to gamma-radiation. Clin Cancer Res. 2005;11:4479–4486
  48. Cuneo KC, Geng L, Fu A, Orton D, Hallahan DE, Chakravarthy AB. SU11248 (sunitinib) sensitizes pancreatic cancer to the cytotoxic effects of ionizing radiation. Int J Radiat Oncol Biol Phys. 2008;71:873–889
  49. Solberg TD, Nearman J, Mullins J, Li S, Baranowska-Kortylewicz J. Correlation between tumour growth delay and expression of cancer and host VEGF; VEGFR2; and osteopontin in response to radiotherapy. Int J Radiat Oncol Biol Phys. 2008;72:918–926
  50. Meyn RE, Munshi A, Haymach JV, Milas L, Ang KK. Receptor signaling as a regulatory mechanism of DNA repair. Radiother Oncol. 2009;92:316–322
  51. Tanaka T, Munshi A, Brooks C, Liu J, Hobbs ML, Meyn RE. Gefitinib radiosensitizes non-small cell lung cancer cells by suppressing cellular DNA repair capacity. Clin Cancer Res. 2008;14:1266–1273
  52. Rodemann HP, Dittmann K, Toulany M. Radiation-induced EGFR-signaling and control of DNA-damage repair. Int J Radiat Biol. 2007;83:781–791
  53. Chen DJ, Nirodi CS. The epidermal growth factor receptor: a role in repair of radiation-induced DNA damage. Clin Cancer Res. 2007;13:6555–6560
  54. Toulany M, Kasten-Pisula U, Brammer I, Wang S, Chen J, Dittmann K, et al. Blockage of epidermal growth factor receptor-phosphatidylinositol 3-kinase-AKT signaling increases radiosensitivity of K-RAS mutated human tumour cells in vitro by affecting DNA repair. Clin Cancer Res. 2006;12:4119–4126
  55. Florczak U, Toulany M, Kehlbach R, Rodemann HP. 2-Methoxyestradiol-induced radiosensitization is independent of SOD but depends on inhibition of Akt and DNA-PKcs activities. Radiother Oncol. 2009;92:334–338
  56. Dittmann K, Mayer C, Kehlbach R, Rodemann HP. Radiation-induced caveolin-1 associated EGFR internalization is linked with nuclear EGFR transport and activation of DNA-PK. Mol Cancer. 2008;7:69
  57. Wanner G, Mayer C, Kehlbach R, Rodemann HP, Dittmann K. Activation of protein kinase Cepsilon stimulates DNA-repair via epidermal growth factor receptor nuclear accumulation. Radiother Oncol. 2008;86:383–390
  58. Dittmann KH, Mayer C, Ohneseit PA, Raju U, Andratschke NH, Milas L, et al. Celecoxib induced tumour cell radiosensitization by inhibiting radiation induced nuclear EGFR transport and DNA-repair: a COX-2 independent mechanism. Int J Radiat Oncol Biol Phys. 2008;70:203–212
  59. Baumann M, Krause M, Dikomey E, Dittmann K, Dörr W, Kasten-Pisula U, et al. EGFR-targeted anti-cancer drugs in radiotherapy: preclinical evaluation of mechanisms. Radiother Oncol. 2007;83:238–248
  60. Cordes N, Park CC. Beta1 integrin as a molecular therapeutic target. Int J Radiat Biol. 2007;83:753–760
  61. Monferran S, Skuli N, Delmas C, Favre G, Bonnet J, Cohen-Jonathan-Moyal E, et al. Alphavbeta3 and alphavbeta5 integrins control glioma cell response to ionising radiation through ILK and RhoB. Int J Cancer. 2008;123:357–364
  62. Sandfort V, Koch U, Cordes N. Cell adhesion-mediated radioresistance revisited. Int J Radiat Biol. 2007;83:727–732
  63. Hehlgans S, Eke I, Deuse Y, Cordes N. Integrin-linked kinase: dispensable for radiation survival of three-dimensionally cultured fibroblasts. Radiother Oncol. 2008;86:329–335
  64. Hess F, Estrugo D, Fischer A, Belka C, Cordes N. Integrin-linked kinase interacts with caspase-9 and -8 in an adhesion-dependent manner for promoting radiation-induced apoptosis in human leukemia cells. Oncogene. 2007;26:1372–1384
  65. Calveley VL, Khan MA, Yeung IW, Vandyk J, Hill RP. Partial volume rat lung irradiation: temporal fluctuations of in-field and out-of-field DNA damage and inflammatory cytokines following irradiation. Int J Radiat Biol. 2005;81:887–899
  66. Rodemann HP, Blaese MA. Responses of normal cells to ionizing radiation. Semin Radiat Oncol. 2007;17:81–88
  67. Kruse JJ, Floot BG, te Poele JA, Russell NS, Stewart FA. Radiation-induced activation of TGF-beta signaling pathways in relation to vascular damage in mouse kidneys. Radiat Res. 2009;171:188–197
  68. Scharpfenecker M, Kruse JJ, Sprong D, Russell NS, Ten Dijke P, Stewart FA. Ionizing radiation shifts the PAI-1/ID-1 balance and activates notch signaling in endothelial cells. Int J Radiat Oncol Biol Phys. 2009;73:506–513
  69. Scharpfenecker M, Floot B, Russell NS, Ten Dijke P, Stewart FA. Endoglin haploinsufficiency reduces radiation-induced fibrosis and telangiectasia formation in mouse kidneys. Radiother Oncol. 2009;92:484–491
  70. Arenas M, Gil F, Gironella M, Hernández V, Biete A, Piqué JM, et al. Time course of anti-inflammatory effect of low-dose radiotherapy: correlation with TGF-beta(1) expression. Radiother Oncol. 2008;86:399–406
  71. Wiegman EM, Blaese MA, Loeffler H, Coppes RP, Rodemann HP. TGFbeta-1 dependent fast stimulation of ATM and p53 phosphorylation following exposure to ionizing radiation does not involve TGFbeta-receptor I signalling. Radiother Oncol. 2007;83:289–295
  72. Kirshner J, Jobling MF, Pajares MJ, Ravani SA, Glick AB, Lavin MJ, et al. Inhibition of transforming growth factor-beta1 signaling attenuates ataxia telangiectasia mutated activity in response to genotoxic stress. Cancer Res. 2006;66:10861–10869
  73. Fournier C, Winter M, Zahnreich S, Nasonova E, Melnikova L, Ritter S. Interrelation amongst differentiation, senescence and genetic instability in long-term cultures of fibroblasts exposed to different radiation qualities. Radiother Oncol. 2007;83:277–282
  74. Ruan K, Song G, Ouyang G. Role of hypoxia in the hallmarks of human cancer. J Cell Biochem. 2009;107:1053–1062
  75. Wouters A, Pauwels B, Lardon F, Vermorken JB. Review: implications of in vitro research on the effect of radiotherapy and chemotherapy under hypoxic conditions. Oncologist. 2007;12:690–712
  76. Rockwell S, Dobrucki IT, Kim EY, Marrison ST, Vu VT. Hypoxia and radiation therapy: past history; ongoing research; and future promise. Curr Mol Med. 2009;9:442–458
  77. Dewhirst MW, Cao Y, Moeller B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer. 2008;8:425–437
  78. Overgaard J. Hypoxic radiosensitization: adored and ignored. J Clin Oncol. 2007;25:4066–4074
  79. Feron O. Pyruvate into lactate and back: from the Warburg effect to symbiotic energy fuel exchange in cancer cells. Radiother Oncol. 2009;92:329–333
  80. Rouschop KM, Ramaekers CH, Schaaf MB, Keulers TG, Savelkouls KG, Lambin P, et al. Autophagy is required during cycling hypoxia to lower production of reactive oxygen species. Radiother Oncol. 2009;92:411–416
  81. Dubois L, Lieuwes NG, Maresca A, Thiry A, Supuran CT, Scozzafava A, et al. Imaging of CA IX with fluorescent labelled sulfonamides distinguishes hypoxic and (re)-oxygenated cells in a xenograft tumour model. Radiother Oncol. 2009;92:423–428
  82. van den Beucken T, Ramaekers CH, Rouschop K, Koritzinsky M, Wouters BG. Deficient carbonic anhydrase 9 expression in UPR-impaired cells is associated with reduced survival in an acidic microenvironment. Radiother Oncol. 2009;92:437–442
  83. Sørensen BS, Horsman MR, Vorum H, Honoré B, Overgaard J, Alsner J. Proteins upregulated by mild and severe hypoxia in squamous cell carcinomas in vitro identified by proteomics. Radiother Oncol. 2009;92:443–449
  84. Mahy P, De Bast M, de Groot T, Cheguillaume A, Gillart J, Haustermans K, et al. Comparative pharmacokinetics; biodistribution; metabolism and hypoxia-dependent uptake of [18F]-EF3 and [18F]-MISO in rodent tumour models. Radiother Oncol. 2008;89:353–360
  85. Murata R, Tsujitani M, Horsman MR. Enhanced local tumour control after single or fractionated radiation treatment using the hypoxic cell radiosensitizer doranidazole. Radiother Oncol. 2008;87:331–338
  86. Sonveaux P. Provascular strategy: targeting functional adaptations of mature blood vessels in tumours to selectively influence the tumour vascular reactivity and improve cancer treatment. Radiother Oncol. 2008;86:300–313
  87. Bache M, Reddemann R, Said HM, Holzhausen HJ, Taubert H, Becker A, et al. Immunohistochemical detection of osteopontin in advanced head-and-neck cancer: prognostic role and correlation with oxygen electrode measurements; hypoxia-inducible-factor-1alpha-related markers; and hemoglobin levels. Int J Radiat Oncol Biol Phys. 2006;66:1481–1487
  88. Goethals L, Debucquoy A, Perneel C, Geboes K, Ectors N, De Schutter H, et al. Hypoxia in human colorectal adenocarcinoma: comparison between extrinsic and potential intrinsic hypoxia markers. Int J Radiat Oncol Biol Phys. 2006;65:246–254
  89. Rosenberg A, Knox S. Radiation sensitization with redox modulators: a promising approach. Int J Radiat Oncol Biol Phys. 2006;64:343–354
  90. Busk M, Horsman MR, Jakobsen S, Keiding S, van der Kogel AJ, Bussink J, et al. Imaging hypoxia in xenografted and murine tumours with 18F-fluoroazomycin arabinoside: a comparative study involving microPET; autoradiography; PO2-polarography; and fluorescence microscopy. Int J Radiat Oncol Biol Phys. 2008;70:1202–1212
  91. Bayer C, Schilling D, Hoetzel J, Egermann HP, Zips D, Yaromina A, et al. PAI-1 levels predict response to fractionated irradiation in 10 human squamous cell carcinoma lines of the head and neck. Radiother Oncol. 2008;86:338–361
  92. Fujii H, Sakata K, Katsumata Y, Sato R, Kinouchi M, Someya M, et al. Tissue oxygenation in a murine SCC VII tumor after X-ray irradiation as determined by EPR spectroscopy. Radiother Oncol. 2008;86:354–360
  93. Tomita N, Shibamoto Y, Ito M, Ogino H, Sugie C, Ayakawa S, et al. Biological effect of intermittent radiation exposure in vivo: recovery from sublethal damage versus reoxygenation. Radiother Oncol. 2008;86:369–374
  94. Dewhirst MW, Cao Y, Li CY, Moeller B. Exploring the role of HIF-1 in early angiogenesis and response to radiotherapy. Radiother Oncol. 2007;83:249–255
  95. Eschmann SM, Paulsen F, Bedeshem C, Machulla HJ, Hehr T, Bamberg M, et al. Hypoxia-imaging with (18)F-misonidazole and PET: changes of kinetics during radiotherapy of head-and-neck cancer. Radiother Oncol. 2007;83:406–410
  96. Magagnin MG, Sergeant K, van den Beucken T, Rouschop KM, Jutten B, Seigneuric R, et al. Proteomic analysis of gene expression following hypoxia and reoxygenation reveals proteins involved in the recovery from endoplasmic reticulum and oxidative stress. Radiother Oncol. 2007;83:340–345
  97. Weppler SA, Li Y, Dubois L, Lieuwes N, Jutten B, Lambin P, et al. Expression of EGFR variant vIII promotes both radiation resistance and hypoxia tolerance. Radiother Oncol. 2007;83:333–339
  98. Dubois L, Douma K, Supuran CT, Chiu RK, van Zandvoort MA, Pastoreková S, et al. Imaging the hypoxia surrogate marker CA IX requires expression and catalytic activity for binding fluorescent sulfonamide inhibitors. Radiother Oncol. 2007;83:367–373
  99. Schütze C, Bergmann R, Yaromina A, Hessel F, Kotzerke J, Steinbach J, et al. Effect of increase of radiation dose on local control relates to pre-treatment FDG uptake in FaDu tumours in nude mice. Radiother Oncol. 2007;83:311–315
  100. van den Beucken T, Magagnin MG, Savelkouls K, Lambin P, Koritzinsky M, Wouters BG. Regulation of Cited2 expression provides a functional link between translational and transcriptional responses during hypoxia. Radiother Oncol. 2007;83:346–352
  101. Ahn GO, Brown JM. Matrix metalloproteinase-9 is required for tumour vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells. Cancer Cell. 2008;13:193–205
  102. Greenberger JS, Epperly M. Bone marrow-derived stem cells and radiation response. Semin Radiat Oncol. 2009;19:133–139
  103. Coppes RP, van der Goot A, Lombaert IM. Stem cell therapy to reduce radiation-induced normal tissue damage. Semin Radiat Oncol. 2009;19:112–121
  104. Feng J, Coppes RP. Can we rescue salivary gland function after irradiation?. Sci World J. 2008;8:959–962
  105. Baumann M, Krause M, Hill R. Exploring the role of cancer stem cells in radioresistance. Nat Rev Cancer. 2008;8:545–554
  106. Yaromina A, Krause M, Thames H, Rosner A, Krause M, Hessel F, et al. Pre-treatment number of clonogenic cells and their radiosensitivity are major determinants of local tumour control after fractionated irradiation. Radiother Oncol. 2007;83:304–310
  107. Seigneuric R, Starmans MH, Fung G, Krishnapuram B, Nuyten DS, van Erk A, et al Impact of supervised gene signatures of early hypoxia on patient survival. Radiother Oncol. 2007;83:374–382
  108. Begg A, van der Kogel A. Clinical radiobiology in 2008. Radiother Oncol. 2008;86:295–299
  109. Starmans MH, Zips D, Wouters BG, Baumann M, Lambin P. The use of a comprehensive tumour xenograft dataset to validate gene signatures relevant for radiation response. Radiother Oncol. 2009;92:417–422
  110. Watanabe H, Mogushi K, Miura M, Yoshimura R, Kurabayashi T, Shibuya H, et al. Prediction of lymphatic metastasis based on gene expression profile analysis after brachytherapy for early-stage oral tongue carcinoma. Radiother Oncol. 2008;87:237–242
  111. Rachidi W, Harfourche G, Lemaitre G, Amiot F, Vaigot P, Martin MT. Sensing radiosensitivity of human epidermal stem cells. Radiother Oncol. 2007;83:267–276
  112. Klopp AH, Jhingran A, Ramdas L, Story MD, Broadus RR, Lu KH, et al. Gene expression changes in cervical squamous cell carcinoma after initiation of chemoradiation and correlation with clinical outcome. Int J Radiat Oncol Biol Phys. 2008;71:226–236
  113. Pramana J, Van den Brekel MW, van Velthuysen ML, Wessels LF, Nuyten DS, Hofland I, et al. Gene expression profiling to predict outcome after chemoradiation in head and neck cancer. Int J Radiat Oncol Biol Phys. 2007;69:1544–1552
  114. Ishikawa K, Koyama-Saegusa K, Otsuka Y, Ishikawa A, Kawai S, Yasuda K, et al. Gene expression profile changes correlating with radioresistance in human cell lines. Int J Radiat Oncol Biol Phys. 2006;65:234–245
  115. Rødningen OK, Børresen-Dale AL, Alsner J, Hastie T, Overgaard J. Radiation-induced gene expression in human subcutaneous fibroblasts is predictive of radiation-induced fibrosis. Radiother Oncol. 2008;86:314–320
  116. Eriksen JG, Overgaard J. Danish Head and Neck Cancer Study Group (DAHANCA). Lack of prognostic and predictive value of CA IX in radiotherapy of squamous cell carcinoma of the head and neck with known modifiable hypoxia: an evaluation of the DAHANCA 5 study. Radiother Oncol. 2007;83:383–388
  117. Landmark H, Nahas SA, Aarøe J, Gatti R, Børresen-Dale AL, Rødningen OK. Transcriptional response to ionizing radiation in human radiation sensitive cell lines. Radiother Oncol. 2007;83:256–260
  118. Barnett GC, West CM, Dunning AM, Elliott RM, Coles CE, Pharoah PD, et al. Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype. Nat Rev Cancer. 2009;9:134–142
  119. Rødningen OK, Børresen-Dale AL, Alsner J, Hastie T, Overgaard J. Radiation-induced gene expression in human subcutaneous fibroblasts is predictive of radiation-induced fibrosis. Radiother Oncol. 2008;86:314–320
  120. Sørensen BS, Alsner J, Overgaard J, Horsman MR. Hypoxia induced expression of endogenous markers in vitro is highly influenced by pH. Radiother Oncol. 2007;83:362–366
  121. Alsner J, Rødningen OK, Overgaard J. Differential gene expression before and after ionizing radiation of subcutaneous fibroblasts identifies breast cancer patients resistant to radiation-induced fibrosis. Radiother Oncol. 2007;83:226–261
  122. Nordsmark M, Eriksen JG, Gebski V, Alsner J, Horsman MR, Overgaard J. Differential risk assessments from five hypoxia specific assays: the basis for biologically adapted individualized radiotherapy in advanced head and neck cancer patients. Radiother Oncol. 2007;83:389–397
  123. Borgmann K, Hoeller U, Nowack S, Bernhard M, Röper B, Brackrock S, et al. Individual radiosensitivity measured with lymphocytes may predict the risk of acute reaction after radiotherapy. Int J Radiat Oncol Biol Phys. 2008;71:256–264
  124. Borgmann K, Haeberle D, Doerk T, Busjahn A, Stephan G, Dikomey E. Genetic determination of chromosomal radiosensitivities in G0- and G2-phase human lymphocytes. Radiother Oncol. 2007;83:196–202
  125. Bieler A, Mantwill K, Holzmüller R, Jürchott K, Kaszubiak A, Stärk S, et al. Impact of radiation therapy on the oncolytic adenovirus dl520: implications on the treatment of glioblastoma. Radiother Oncol. 2008;86:419–427
  126. Aerts HJ, Dubois L, Hackeng TM, Straathof R, Chiu RK, Lieuwes NG, et al. Development and evaluation of a cetuximab-based imaging probe to target EGFR and EGFRvIII. Radiother Oncol. 2007;83:326–332
  127. Krause M, Prager J, Zhou X, Yaromina A, Dörfler A, Eicheler W, et al. EGFR-TK inhibition before radiotherapy reduces tumour volume but does not improve local control: differential response of cancer stem cells and nontumourigenic cells?. Radiother Oncol. 2007;83:316–325
  128. Kong FM, Frey KA, Quint LE, Ten Haken RK, Hayman JA, Kessler M, et al. A pilot study of [18F]fluorodeoxyglucose positron emission tomography scans during and after radiation-based therapy in patients with non small-cell lung cancer. J Clin Oncol. 2007;25:3116–3123
  129. Koritzinsky M, Rouschop KM, van den Beucken T, Magagnin MG, Savelkouls K, Lambin P, et al. Phosphorylation of eIF2alpha is required for mRNA translation inhibition and survival during moderate hypoxia. Radiother Oncol. 2007;83:353–361
  130. Said HM, Hagemann C, Staab A, Stojic J, Kühnel S, Vince GH, et al. Expression patterns of the hypoxia-related genes osteopontin; CA9; erythropoietin; VEGF and HIF-1alpha in human glioma in vitro and in vivo. Radiother Oncol. 2007;83:398–405
  131. Zaidi SH, Huddart RA, Harrington KJ. Novel targeted radiosensitisers in cancer treatment. Curr Drug Discov Technol. 2009;6:103–134
  132. Harari PM, Wheeler DL, Grandis JR. Molecular target approaches in head and neck cancer: epidermal growth factor receptor and beyond. Semin Radiat Oncol. 2009;19:63–68
  133. Said HM, Hagemann C, Staab A, Stojic J, Kühnel S, Vince GH, et al. Expression patterns of the hypoxia-related genes osteopontin; CA9; erythropoietin; VEGF and HIF-1alpha in human glioma in vitro and in vivo. Radiother Oncol. 2007;83:398–405
  134. Harrington K, Jankowska P, Hingorani M. Molecular biology for the radiation oncologist: the 5Rs of radiobiology meet the hallmarks of cancer. Clin Oncol (R Coll Radiol). 2007;19:561–571
  135. Roper J, Bowsher J, Yin FF. On-board SPECT for localizing functional targets: a simulation study. Med Phys. 2009;36:1727–1735
  136. Thakur ML. Genomic biomarkers for molecular imaging: predicting the future. Semin Nucl Med. 2009;39236–39246
  137. Vlashi E, Kim K, Lagadec C, Donna LD, McDonald JT, Eghbali M, et al. In vivo imaging; tracking; and targeting of cancer stem cells. J Natl Cancer Inst. 2009;101:350–359
  138. Zhang L, Bhojani MS, Ross BD, Rehemtulla A. Molecular imaging of protein kinases. Cell Cycle. 2008;7:314–317
  139. Meyer A, Wilhelm B, Dörk T, Bremer M, Baumann R, Karstens JH, et al. ATM missense variant P1054R predisposes to prostate cancer. Radiother Oncol. 2007;83:283–288
  140. Overgaard J, Baumann M. Translational research in radiotherapy – getting closer to the bedside. Radiother Oncol. 2007;83:217–229
  141. Supiot S, Zhao H, Wiman K, Hill RP, Bristow RG. PRIMA-1(met) radiosensitizes prostate cancer cells independent of their MTp53-status. Radiother Oncol. 2008;86:407–411
  142. Burlage FR, Roesink JM, Faber H, Vissink A, Langendijk JA, Kampinga HH, et al. Optimum dose range for the amelioration of long term radiation-induced hyposalivation using prophylactic pilocarpine treatment. Radiother Oncol. 2008;86:347–353

PII: S0167-8140(09)00459-9

doi: 10.1016/j.radonc.2009.08.023

Radiotherapy & Oncology
Volume 92, Issue 3 , Pages 293-298 , September 2009

Article Tools